Literature DB >> 14996099

Quality of life and disease severity are correlated in children with atopic dermatitis.

M A Ben-Gashir1, P T Seed, R J Hay.   

Abstract

BACKGROUND: Atopic dermatitis (AD) in children may affect their daily activities and normal development. It can have a negative impact on the child's behaviour. Little is known about the quality of life (QOL) in children and its relationship to disease severity, especially from a community-based study.
OBJECTIVES: To document the impact of AD on children's QOL and its relationship to disease severity.
METHODS: The targeted population, before recruitment, comprised children with AD aged 5-10 years from a primary care setting. Their general practitioners identified potential patients and the U.K. diagnostic criteria for AD were used to verify the diagnosis. Eczema severity was assessed using the SCORAD (SCORing Atopic Dermatitis) index. The Children's Dermatology Life Quality Index (CDLQI) was used to quantify the impact of AD on children's QOL. These two parameters were evaluated on two occasions 6 months apart. The Spearman correlation coefficient and multiple regressions were used in statistical analysis.
RESULTS: Of the 116 children attending the first QOL assessment visit, 78 (mean age 8.6 years, 44 girls and 34 boys) were able to complete the CDLQI. Of these 78 children, 71 (91%) attended the second visit, and were included in the analysis. The children's QOL was affected in 65 (92%) and 55 (77%) children attending the first and second visits, respectively. The CDLQI was significantly correlated with the SCORAD at the first and second visits (r=0.52, P<0.001 and r=0.59, P<0.001, respectively). Each unit change in the SCORAD was associated with a 0.12 (95% confidence interval 0.04-0.19, P=0.004) unit change in the children's QOL.
CONCLUSIONS: We have shown a positive correlation between children's QOL and disease severity on cross-sectional and over time observation. This highlights the impact of AD on children's life. It also draws attention to the long-term effect on children's behaviour and development. In addition, these findings may imply that the CDLQI could be used as an extra measure of disease assessment in clinical practice and research studies.

Entities:  

Mesh:

Year:  2004        PMID: 14996099     DOI: 10.1111/j.1365-2133.2004.05776.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  35 in total

1.  Cost-effectiveness model for a specific mixture of prebiotics in The Netherlands.

Authors:  I Lenoir-Wijnkoop; W M C van Aalderen; G Boehm; D Klaassen; A B Sprikkelman; M J C Nuijten
Journal:  Eur J Health Econ       Date:  2010-12-17

2.  Comorbidity in Atopic Dermatitis.

Authors:  Eric L Simpson
Journal:  Curr Dermatol Rep       Date:  2012-03-01

Review 3.  Quality-of-life outcomes and measurement in childhood atopic dermatitis.

Authors:  Sarah L Chamlin; Mary-Margaret Chren
Journal:  Immunol Allergy Clin North Am       Date:  2010-07-01       Impact factor: 3.479

4.  CDLQI, SCORAD and NESS: are they correlated?

Authors:  K L E Hon; W Y C Kam; M C A Lam; T F Leung; P C Ng
Journal:  Qual Life Res       Date:  2006-07-07       Impact factor: 4.147

5.  Quality of life and disease severity are correlated in patients with atopic dermatitis.

Authors:  Dong Ha Kim; Kapsok Li; Seong Jun Seo; Sun Jin Jo; Hyeon Woo Yim; Churl Min Kim; Kyu Han Kim; Do Won Kim; Moon-Bum Kim; Jin Woo Kim; Young Suck Ro; Young Lip Park; Chun Wook Park; Seung-Chul Lee; Sang Hyun Cho
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

6.  Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids.

Authors:  Leon H Kircik; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-12

7.  Overexpression of AQP3 and AQP10 in the skin exacerbates psoriasiform acanthosis.

Authors:  David C Soler; Andrew E Young; Alexis D Griffith; Ping Fu Fu; Kevin D Cooper; Thomas S McCormick; Daniel L Popkin
Journal:  Exp Dermatol       Date:  2017-04-21       Impact factor: 3.960

Review 8.  Therapeutic Benefits of Natural Ingredients for Atopic Dermatitis.

Authors:  George Man; Li-Zhi Hu; Peter M Elias; Mao-Qiang Man
Journal:  Chin J Integr Med       Date:  2017-09-01       Impact factor: 1.978

9.  Mental health comorbidity in patients with atopic dermatitis.

Authors:  Pouya Yaghmaie; Caroline W Koudelka; Eric L Simpson
Journal:  J Allergy Clin Immunol       Date:  2012-12-13       Impact factor: 10.793

10.  Air pollution and exacerbation of skin itching and sleep disturbance in Iranian atopic dermatitis patients.

Authors:  Pegah Nakhjirgan; Masoumeh Mahmoodi; Homa Kashani; Alireza Firooz; Ramin Nabizadeh; Majid Kermani; Masud Yunesian
Journal:  J Environ Health Sci Eng       Date:  2019-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.